ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00048633
Recruitment Status : Completed
First Posted : November 6, 2002
Last Update Posted : May 23, 2012
Sponsor:
Information provided by (Responsible Party):
QLT Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2003
  Actual Study Completion Date : June 2003